<DOC>
	<DOCNO>NCT01298752</DOCNO>
	<brief_summary>The objective study compare safety efficacy Mapracorat Ophthalmic Suspension , 3 % vehicle treatment postoperative inflammation pain follow cataract surgery .</brief_summary>
	<brief_title>Mapracorat Ophthalmic Suspension , 3 % Treatment Ocular Inflammation Following Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<criteria>Subjects candidate routine , uncomplicated cataract surgery . Subjects must willing wait undergo cataract surgery fellow eye study complete . Subjects expect require treatment systemic ocular ( either eye ) drug specify protocol 18 day follow cataract surgery systemic ocular corticosteroid within 14 day prior cataract surgery . Subjects know hypersensitivity contraindication study drug ( ) component . Subjects severe/serious ocular condition history/presence chronic generalize systemic disease Investigator feel might increase risk subject confound result ( ) study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>